Sign up for News by Email
All Releases
View Summary Encouraging Initial Data From Ongoing Phase 1/2 Trial of TH-302 Plus Bortezomib (Velcade(R)) Plus Dexamethasone ("TBorD") in Patients With Relapsed/Refractory Multiple Myeloma Presented at ASH Annual Meeting
Dec 6, 2014
PDF 16.2 KB
View Summary Threshold Pharmaceuticals Announces Presentations and Webcasts at Upcoming Investor Meetings in December 2014
Nov 25, 2014
PDF 9.5 KB
View Summary Threshold Pharmaceuticals Announces Phase 1/2 Interim Data Signaling Activity of TH-302 Plus Bevacizumab (Avastin(R)) in Patients With Glioblastoma
Nov 17, 2014
PDF 17.7 KB
View Summary Threshold Pharmaceuticals Receives FDA Fast Track Designation for TH-302 for the Treatment of Previously Untreated Patients With Metastatic or Locally Advanced Unresectable Soft Tissue Sarcoma
Nov 11, 2014
PDF 15.4 KB
View Summary Threshold Pharmaceuticals Announces Presentation and Webcast at the Stifel 2014 Healthcare Conference
Nov 10, 2014
PDF 9.4 KB
View Summary Threshold Pharmaceuticals Announces New Phase 1/2 Data on TH-302 in Multiple Myeloma to Be Presented at the 2014 ASH Annual Meeting
Nov 6, 2014
PDF 11.5 KB
View Summary Threshold Pharmaceuticals Announces New Phase 1/2 Data on TH-302 in Glioblastoma to be Presented at the 2014 SNO Annual Meeting
Nov 3, 2014
PDF 12.4 KB
View Summary Threshold Pharmaceuticals Reports Third Quarter 2014 Financial and Operational Results
Nov 3, 2014
PDF 23.7 KB
View Summary Threshold Pharmaceuticals' Partner Merck KGaA, Darmstadt, Germany, Completes Target Enrollment in the TH-302 Phase 3 MAESTRO Study in Patients With Locally Advanced or Metastatic Pancreatic Adenocarcinoma
Nov 3, 2014
PDF 14.7 KB
View Summary Threshold Pharmaceuticals Announces Its Phase 3 Trial of TH-302 in Patients With Advanced Soft Tissue Sarcoma Will Continue as Planned Following Protocol-Specified Interim Analysis
Sep 22, 2014
PDF 15.6 KB
View Summary Threshold Pharmaceuticals Announces Presentation and Webcast at the Rodman & Renshaw 16th Annual Global Investment Conference
Sep 2, 2014
PDF 9.4 KB
View Summary Threshold Pharmaceuticals Reports Second Quarter 2014 Financial and Operational Results
Aug 1, 2014
PDF 23.9 KB
View Summary Threshold Announces Initiation of Dosing With TH-302/Bortezomib (Velcade(R))/Dexamethasone ("TBorD") in Final Stage of Ongoing Phase 1/2 Trial of Patients With Relapsed/Refractory Multiple Myeloma
Jul 9, 2014
PDF 56.0 KB
View Summary Threshold Pharmaceuticals Initiates 440-Patient, Randomized, Double-Blind, Placebo-Controlled Trial of TH-302 in Combination With Pemetrexed in Advanced Non-Squamous Non-Small Cell Lung Cancer
Jul 1, 2014
PDF 15.9 KB
View Summary Threshold Pharmaceuticals Announces Presentation and Webcast at the Jefferies Global Healthcare Conference
May 30, 2014
PDF 9.5 KB
View Summary Threshold Announces Data From Ongoing Phase 1/2 Trial of TH-302 Plus Bevacizumab (Avastin(R)) in Patients With Recurrent Glioblastoma
May 30, 2014
PDF 18.7 KB
View Summary Threshold Announces Data From Ongoing Phase 1/2 Trial of TH-302 Plus Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma
May 30, 2014
PDF 18.8 KB
View Summary Threshold Announces Webcast of Analyst Event on Sunday, June 1, 2014
May 27, 2014
PDF 14.4 KB
View Summary Threshold Announces Clinical Data on TH-302 in Glioblastoma and Relapsed/Refractory Multiple Myeloma to Be Presented at ASCO 2014
May 14, 2014
PDF 14.0 KB
View Summary Threshold Pharmaceuticals Announces Presentation and Webcast at the UBS Global Healthcare Conference
May 13, 2014
PDF 9.4 KB
Showing 1-20 of 256 Page: 1 2 3 4 5 ... 13  Next 20
You are now leaving this website. If you would like to continue, click Continue.
CancelContinue